01—Abstract
Summary
Summary of the 10-Q filed June 1, 2026. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. reported robust financial results for the period ended April 30, 2026.
Total net revenue increased by 10% year-over-year for the quarter and 8% for the six-month period, driven by broad-based growth across all segments and geographic regions. Net income saw a significant increase, reaching $339 milliona in the quarter and $644 million year-to-date, up from $215 million and $533 million in the prior year, respectively. The company continues to execute on its strategic priorities, including investing in research and development and expanding its product and service portfolio.
A notable event was the definitive agreement to acquire BC Midco I, Inc. for approximately $950 millionb, which is expected to close by the end of fiscal year 2026 and will be integrated into the Life Sciences and Diagnostics Markets segment. Agilent also announced its board declared a quarterly dividend of $0.255 per share. Despite global economic uncertainties, the company has effectively mitigated impacts from geopolitical tensions and tariffs through strategic initiatives.
02—Key points
Key Highlights
- Total net revenue increased by 10% in the third quarter and 8% in the first six months of fiscal year 2026 compared to the prior year.
- Net income surged to $339 million in the quarter and $644 million year-to-date, demonstrating strong profitability.
- The company announced a definitive agreement to acquire BC Midco I, Inc. ('Biocare') for approximately $950 million in cash, strengthening its Life Sciences and Diagnostics Markets segment.
- All three operating segments (Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets) contributed to revenue growth.
- The company continued its return of capital to shareholders with a declared quarterly dividend of $0.255 per share.
- Agilent Technologies has effectively navigated global economic uncertainties, including geopolitical tensions and tariff impacts, through strategic mitigation efforts.
- Operating margin improved to 21.7% in the quarter and 18.0% in the prior year, indicating enhanced operational efficiency.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2026, Agilent Technologies, Inc. kept $0.18.
- Revenue$1.83B100.0%
- Cost of revenue−$845.0M46.0%
- Gross profit$990.0M54.0%
- Operating costs−$591.0M32.2%
- Operating income$399.0M21.7%
- Interest, other & tax−$60.0M3.3%
- Net income$339.0M18.5%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2026filed June 1, 2026Financial Statements
Q2 FY2026 against Q2 FY2025
| Line item | Q2 FY2026Q2 FY2025 | Change |
|---|---|---|
| Revenue | $1.83B$1.67B | +10.0% |
| Cost of Revenue | $845.00M$802.00M | +5.4% |
| Gross Profit | $990.00M$866.00M | +14.3% |
| R&D Expenses | $126.00M$112.00M | +12.5% |
| SG&A Expenses | $465.00M$454.00M | +2.4% |
| Operating Expenses | $1.44B$1.37B | +5.0% |
| Operating Income | $399.00M$300.00M | +33.0% |
| Interest Expense | $25.00M$29.00M | −13.8% |
| Net Income | $339.00M$215.00M | +57.7% |
| EPS (Basic) | $1.20$0.75 | +60.0% |
| EPS (Diluted) | $1.20$0.75 | +60.0% |
| Shares Outstanding (Basic) | 282.00M285.00M | −1.1% |
| Shares Outstanding (Diluted) | 283.00M285.00M | −0.7% |
05—Questions
Frequently Asked Questions
What was Agilent's revenue performance for the reported period?
Agilent Technologies reported a 10% increase in total net revenue for the three months ended April 30, 2026, reaching $1.835 billion, and an 8% increase for the six months ended April 30, 2026, totaling $3.633 billion, compared to the same periods in the prior year. This growth was broad-based across all segments and geographic regions.
What is the significance of the announced acquisition of Biocare?
Agilent announced a definitive agreement to acquire BC Midco I, Inc. ('Biocare') for approximately $950 million in cash. This acquisition is strategically important as Biocare is a leading provider of clinical and research solutions and will be integrated into Agilent's Life Sciences and Diagnostics Markets segment, further strengthening its position in this key area.
How did Agilent manage global economic headwinds like tariffs and geopolitical tensions?
Agilent successfully mitigated the adverse impacts of global tariffs and geopolitical tensions, including the Middle East conflict. The company implemented various strategies such as supply chain optimization, targeted pricing actions, and cost-efficiency initiatives to protect margins and sustain long-term growth, ensuring these external factors did not materially affect their operational results.
What is Agilent's outlook for the coming periods?
The company remains optimistic about the long-term health of its key end markets and continues to invest in research and development and expand its product and solutions portfolio. They are particularly focused on enhancing customer experience and driving productivity improvements, anticipating a normalization in customer capital spending.
06—Continue